Invivyd Announces Inclusion of PEMGARDA in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
| IVVD Stock | USD 0.73 0.04 5.80% |
About 56% of all Invivyd's shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Invivyd suggests that some traders are interested. The current market sentiment, together with Invivyd's historical and current headlines, can help investors time the market. In addition, many technical investors use Invivyd stock news signals to limit their universe of possible portfolio assets.
WALTHAM, Mass., May 23, 2025 -- Invivyd, Inc. , today announced that PEMGARDA , its investigational...
Read at globenewswire.com
 |
Invivyd Fundamental Analysis
We analyze Invivyd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Invivyd using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Invivyd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Invivyd is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Invivyd Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Invivyd stock to make a market-neutral strategy. Peer analysis of Invivyd could also be used in its relative valuation, which is a method of valuing Invivyd by comparing valuation metrics with similar companies.
Peers
Invivyd Related Equities
| ABSI | Absci Corp | 2.47 | ||||
| PRAX | Praxis Precision | 0.24 | ||||
| ERAS | Erasca | 2.11 | ||||
| CADL | Candel Therapeutics | 2.48 | ||||
| ADVM | Adverum Biotechnologies | 2.93 | ||||
| GLUE | Monte Rosa | 3.23 | ||||
| KZR | Kezar Life | 5.15 | ||||
| PASG | Passage Bio | 10.59 |
Complementary Tools for Invivyd Stock analysis
When running Invivyd's price analysis, check to measure Invivyd's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invivyd is operating at the current time. Most of Invivyd's value examination focuses on studying past and present price action to predict the probability of Invivyd's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invivyd's price. Additionally, you may evaluate how the addition of Invivyd to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |